These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8202964)

  • 41. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram.
    Markowitz JS; DeVane CL; Liston HL; Montgomery SA
    Int Clin Psychopharmacol; 2000 Nov; 15(6):329-33. PubMed ID: 11110008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Escitalopram versus placebo in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
    Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age.
    Kauffman RP; Castracane VD; White DL; Baldock SD; Owens R
    Gynecol Endocrinol; 2005 Sep; 21(3):129-37. PubMed ID: 16335904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and side effects of methylphenidate for poststroke depression.
    Lazarus LW; Winemiller DR; Lingam VR; Neyman I; Hartman C; Abassian M; Kartan U; Groves L; Fawcett J
    J Clin Psychiatry; 1992 Dec; 53(12):447-9. PubMed ID: 1487474
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quetiapine as combination treatment with citalopram in unipolar depression with prominent somatic symptoms: a randomised, double-blind, placebo-controlled pilot study.
    Quante A; Regen F; Schindler F; Volkmer K; Severus E; Urbanek C; Luborzewski A; Roepke S; Anghelescu I
    Psychiatr Danub; 2013 Sep; 25(3):214-20. PubMed ID: 24048387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Different interventions for post-ischaemic stroke depression in different time periods: a single-blind randomized controlled trial with stratification by time after stroke.
    Gao J; Lin M; Zhao J; Bi S; Ni Z; Shang X
    Clin Rehabil; 2017 Jan; 31(1):71-81. PubMed ID: 26817808
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duloxetine versus citalopram and sertraline in the treatment of poststroke depression, anxiety, and fatigue.
    Karaiskos D; Tzavellas E; Spengos K; Vassilopoulou S; Paparrigopoulos T
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):349-53. PubMed ID: 23037649
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Citalopram in Treating Post-Stroke Depression: A Meta-Analysis.
    Tan S; Huang X; Ding L; Hong H
    Eur Neurol; 2015; 74(3-4):188-201. PubMed ID: 26559658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression.
    Sneed JR; Culang ME; Keilp JG; Rutherford BR; Devanand DP; Roose SP
    Am J Geriatr Psychiatry; 2010 Feb; 18(2):128-35. PubMed ID: 20104069
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of prestroke physical activity and citalopram treatment on poststroke depressive symptoms: a secondary analysis of data from the TALOS randomised controlled trial in Denmark.
    Vestergaard SB; Damsbo AG; Blauenfeldt RA; Johnsen SP; Andersen G; Mortensen JK
    BMJ Open; 2023 Mar; 13(3):e070822. PubMed ID: 36997260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.
    Montgomery SA; Rasmussen JG; Tanghøj P
    Int Clin Psychopharmacol; 1993; 8(3):181-8. PubMed ID: 8263316
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparing the Efficacy of 8 Weeks Treatment of Cipram® and its Generic Citalopram in Patients With Mixed Anxiety-Depressive Disorder.
    Khoonsari H; Oghazian MB; Kargar M; Moin M; Khalili H; Alimadadi A; Torkamandi H; Ghaeli P
    Iran J Psychiatry Behav Sci; 2015 Jun; 9(2):e230. PubMed ID: 26288644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Initial, clinical trial of a new, specific 5-HT reuptake inhibitor, citalopram (Lu 10-171).
    Gottlieb P; Wandall T; Overø KF
    Acta Psychiatr Scand; 1980 Sep; 62(3):236-44. PubMed ID: 6935914
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind double-dummy study of citalopram comparing infusion versus oral administration.
    Baumann P; Nil R; Bertschy G; Jecker A; Brändli H; Morand J; Kasas A; Vuagniaux O; Ramseier F
    J Affect Disord; 1998 Jun; 49(3):203-10. PubMed ID: 9629950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of depression in elderly patients with and without dementia disorders.
    Gottfries CG; Karlsson I; Nyth AL
    Int Clin Psychopharmacol; 1992 Jun; 6 Suppl 5():55-64. PubMed ID: 1431023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of SSRIs in Improving Poststroke Recovery: A Systematic Review and Meta-Analysis.
    Kalbouneh HM; Toubasi AA; Albustanji FH; Obaid YY; Al-Harasis LM
    J Am Heart Assoc; 2022 Jul; 11(13):e025868. PubMed ID: 35730636
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Citalopram as treatment of depression in patients with epilepsy.
    Specchio LM; Iudice A; Specchio N; La Neve A; Spinelli A; Galli R; Rocchi R; Ulivelli M; de Tommaso M; Pizzanelli C; Murri L
    Clin Neuropharmacol; 2004; 27(3):133-6. PubMed ID: 15190237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Results of the citalopram to enhance cognition in Huntington disease trial.
    Beglinger LJ; Adams WH; Langbehn D; Fiedorowicz JG; Jorge R; Biglan K; Caviness J; Olson B; Robinson RG; Kieburtz K; Paulsen JS
    Mov Disord; 2014 Mar; 29(3):401-5. PubMed ID: 24375941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.